NCT02703623 - Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter

Enrollment

196

Participants

Timeline

Start Date

May 18, 2016

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaPSA ProgressionStage IV Prostate Adenocarcinoma AJCC v7

Interventions

DRUG

Abiraterone Acetate

Given PO

DRUG

Apalutamide

Given PO

DRUG

Cabazitaxel

Given IV

DRUG

Carboplatin

Given IV

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Prednisone

Given PO

Trial Locations (3)

77030

M D Anderson Cancer Center, Houston

77094

MD Anderson in Katy, Houston

77478

MD Anderson in Sugar Land, Sugar Land

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER